Köchel, Ricardo; Schwegmann, Katrin; Breyholz, Hans-Jörg; Schäfers, Michael; Wagner, Stefan; Wünsch, Bernhard
Research article (journal) | Peer reviewedThe fibroblast activation protein (FAP) is highly expressed by cancer associated fibroblasts in the microenvironment of tumors. The PET tracer [68Ga]Ga-oncoFAP-DOTAGA (1) is clinically used to detect FAP-positive tumors. In order to improve the imaging properties, fluorinated FAP inhibitors 8, 9, 14, and 21 with polar but nonbasic linkers were designed, synthesized, and biologically evaluated. The PEG-based ligand 21 exhibited particularly high FAP inhibitory activity (IC50 = 13 pM), high selectivity toward related dipeptidyl peptidases, very low log D7.4 value, and high metabolic stability in vitro. Nucleophilic substitution of tosylate 20 led to the PET tracer [18F]21 in 10.8% radiochemical yield and 97.4% radiochemical purity within a total synthesis time of 119 min [18F]21 revealed high stability in human and murine serum. In biodistribution studies in CD-1 mice, [18F]21 showed renal and hepatobiliary elimination. In a mouse xenograft model, considerable accumulation of [18F]21 in FAP-positive HT1080 tumors was observed.
Breyholz, Hans-Jörg | Clinic for Nuclear Medicine |
Köchel, Ricardo Tarik | Professur für Pharmazeutische Chemie (Prof. Wünsch) |
Schäfers, Michael | Clinic for Nuclear Medicine European Institute of Molecular Imaging (EIMI) |
Schwegmann, Katrin | European Institute of Molecular Imaging (EIMI) |
Wagner, Stefan | Clinic for Nuclear Medicine |
Wünsch, Bernhard | Professur für Pharmazeutische Chemie (Prof. Wünsch) |